A single oral dose of Compazine (prochlorperazine) provides relief for roughly 6 to 8 hours, which is why it’s typically dosed three to four times per day. The exact duration depends on which form you take: tablets, injections, or suppositories each work on different timelines.
Duration by Formulation
The form of Compazine you use has a significant impact on how long the effects last. Oral tablets wear off in about 6 to 8 hours. An intramuscular injection can last up to 12 hours, though it may be repeated every 3 to 4 hours for severe nausea. Rectal suppositories, which deliver a larger dose (25 mg compared to the typical 5 to 10 mg oral dose), are spaced 12 hours apart, suggesting their effects last roughly that long.
If you received Compazine through an IV in an emergency room or hospital, the onset is faster but the duration is similar to an injection. For nausea related to migraines, a single IV or intramuscular dose is often all that’s given.
How Long It Stays in Your System
The effects wearing off is not the same as the drug leaving your body entirely. After a single dose, Compazine has an elimination half-life of about 8 to 9 hours. That means half the drug is cleared from your system in that window, and it takes roughly 40 to 45 hours (about five half-lives) for a single dose to be fully eliminated.
If you’ve been taking Compazine regularly for days or weeks, it takes longer to clear. In one study of healthy volunteers, the half-life nearly doubled to about 18 hours after 14 days of use. This means the drug accumulates in your body with repeated dosing, and full clearance after stopping could take several days.
Common Side Effects and How Long They Last
Drowsiness is the side effect most people notice first. It typically tracks with the drug’s active window, so expect it to fade as the dose wears off over 6 to 12 hours depending on your formulation. Dry mouth and mild dizziness follow a similar pattern.
More concerning are movement-related side effects, which Compazine causes at higher rates than many similar medications. Between 25% and 67% of people taking prochlorperazine experience some form of these effects, which can include muscle stiffness, restlessness, or involuntary movements. Acute muscle spasms (dystonia) show up within 48 hours in about half of cases and within 5 days in 90% of cases. A sensation of inner restlessness called akathisia typically develops within 4 weeks of starting the medication.
If you stop taking Compazine after regular use, withdrawal-related restlessness can persist for up to 6 weeks before resolving on its own. With long-term use, a condition called tardive dyskinesia (repetitive, involuntary movements of the face or limbs) can develop and may not fully reverse even after stopping the drug.
Factors That Affect Duration
Several things influence how long Compazine’s effects last for you personally. The drug has low oral bioavailability, meaning your body only absorbs a fraction of what you swallow. Individual differences in liver metabolism can shift the effective duration by an hour or two in either direction.
Older adults tend to process the drug more slowly, which means both the therapeutic effects and side effects can linger longer. Alcohol and other sedating substances amplify and extend drowsiness when combined with Compazine. If you’re taking the drug for nausea and feel it wearing off sooner than expected, the dosing schedule (every 6 to 8 hours for tablets, every 3 to 4 hours for injections) is designed to allow redosing before the previous dose fully fades.
Typical Dosing Schedules
For nausea and vomiting, the standard oral dose is 5 to 10 mg taken every 6 to 8 hours, with a daily cap of 40 mg. That works out to three or four doses per day. Suppositories are dosed at 25 mg every 12 hours, so just twice daily.
When used for anxiety, the maximum drops to 20 mg per day, and treatment is generally limited to 12 weeks. For severe psychiatric conditions, doses can go much higher under close medical supervision.
Compazine is not approved for children under 2 years old or weighing less than 20 pounds. It also carries a boxed warning against use in elderly patients with dementia-related psychosis due to an increased risk of death, with studies showing roughly 4.5% mortality in treated patients compared to 2.6% with placebo over a 10-week period.